Statistics
Publications
42
Citations
6.7K
H-Index
30
Active since
2004
Christopher J. Ott is an author at Harvard University specializing in molecular biology, life sciences, and molecular oncology.
Publications per year
2004–2025
42
42
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
Gang Lu, Richard E. Middleton, Huahang Sun et al. · Science · 2013 · 1.6K citations · Full text
Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer
Shaokun Shu, Charles Y. Lin, Housheng Hansen He et al. · Nature · 2016 · 629 citations · Full text
Medicine, Oncology, Pharmacology +14
BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia
Christopher J. Ott, Nadja Kopp, Liat Bird et al. · Blood · 2012 · 369 citations · Full text
Medicine, Immunology, Oncology +11
1–5 of 42